Hengrui Pharma partners with GSK to develop 12 innovative medicines, boosting globalization for Hengrui and expanding GSK's oncology and RI&I pipeline.
PR NewswireNEW YORK, May 19, 2025
NEW YORK, May 19, 2025 /PRNewswire/ -- J.P. Morgan Life Sciences Private Capital (Trades, Portfolio), the life sciences v
Domestic manufacturing in the pharmaceutical industry has fallen considerably in the last decades, with most active ingredient production moving to China and other countries.
[url="]Aldeyra Therapeutics, Inc.[/url] (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed t
Omnicell, Inc. (Nasdaq: OMCL) (”Omnicell” or the ”Company”), a leader in transforming the pharmacy and nursing care delivery model, today announced tha
On February 21, Jared Holz, Mizuho Securities America's healthcare sector strategist, appeared on CNBC to discuss Trump's tariffs and their effects on the American pharma sector.
We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Analysts. In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against the other pharmaceutical...
GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved PENMENVY (Meningococcal Groups A, B, C, W, and Y Vaccine) f
e2Companies LLC, an innovative provider of integrated solutions for on-site power generation, distribution and energy cost-optimization, and Nabors Energy Tran
The Centers for Disease Control and Prevention abruptly ordered its staff to cease all collaboration with the World Health Organization on Monday, marking a dramatic acceleration of President Donald Trump's executive order to withdraw from the global health body.
Hindustan Unilever Ltd. made a payment of Rs 192.55 crore as part of a total outstanding tax demand of Rs 962.75 crore on Nov. 28, according to an exchange filing on Monday. The tax department had directed the company to make 20% payment of the total outstanding demand on or before Nov. 30, the filing stated. The demand was raised on "account of non-deduction of TDS" during a Rs 3,045-crore deal with GlaxoSmithKline Group entities.